Popular Articles

Oncologic Drugs Advisory Committee Meeting Set By FDA
Medical Industry E-Mail News Service™ -- July 07 2009 -- The US Food & Drug Administration (FDA) has announced that its Oncologic Drugs Advisory Committee will meet on July 15 2009, in Gaithersburg MD, to discuss (1) new drug application (NDA) 022-447, proposed trade name Yondelis (trabectedin) powder, for concentrate for solution for intravenous infusion, Centocor Ortho Biotech Products, L.P., proposed indication in combination with Doxcil (doxorubicin HCl liposome injection), for treating patients with relapsed ovarian cancer; and (2) supplemental new drug application (sNDA) 050-718/S-039, Doxil (doxorubicin HCl liposome injection), for intravenous infusion, Centocor Ortho Biotech Products, L.P., proposed indication in combination with docetaxel for treating patients with locally advanced or metasatic breast cancer who have received prior anthracycline treatment. There is no charge to attend.
drugs without prescription
200 Percent Increase In Cardiovascular Medication In Canada
A new study in the Canadian Medical Association Journal (CMAJ) reports that the number of prescriptions in Canada for cardiovascular medications has been increasing over the last ten years. There has been a 200 percent increase in costs. Overall costs of cardiovascular medications exceeded $5 billion in 2006. And statins accounted for nearly 40 percent of the expenditure.
News of the day
Likelihood Of Survival May Be Improving For Extremely Preterm Infants
Infants born extremely preterm are surviving at a high rate, with about 70 percent of infants born alive between 22 and 26 weeks of gestation in Sweden surviving at least one year, with high rates of interventions being used to improve survival, according to a study in the June 3 issue of JAMA, a theme issue on child and adolescent health.
Cardiovascular

Presentation At AAPM Meeting On Nanoparticles That Package Cancer-killing Isotopes And Deliver Them Into Cancer Cells

A group of researchers at Johns Hopkins University has designed nanoparticles that can carry cancer-treating radioisotopes through the body and deliver them selectively to tumors. Today in Anaheim, CA, they will report the latest results of their research, including studies in animal models, at the 51st meeting of the American Association of Physicists in Medicine (AAPM). The nanoparticles are made with a commercially available product known as "liposomes" -- small chemical spheres made of fatty molecules that can package drugs and other chemicals. Liposomes are a powerful emerging tool in medicine because they can be designed to carry many different drugs and manipulated to control how long they stay in the bloodstream. One type of liposome, Doxil, is already approved by the U.S. Food and Drug Administration (FDA) for delivering Doxorubicin, a chemotherapeutic that is toxic to the heart. The Hopkins scientists are using liposomes that have been modified with antibodies, a class of immune system proteins that recognize and bind to many different microscopic targets -- bacteria, viruses, other proteins, and human cells. Some antibodies specifically bind to cancer cells, and by attaching these cancer-specific antibodies to the liposomes, the scientists have created "immunoliposomes," which will wend their way through the bloodstream and seek out tumors inside the body. When they come into contact with their target cells, they deliver their payload into the cells. "It"s a promising approach to solving the problem of how to deliver more of a therapeutic to cancer cells," says George Sgouros, a radiology professor at Johns Hopkins who led the research. Similar studies by other groups of researchers have already demonstrated how immunoliposomes could be packaged with tiny radioactive tracers used for imaging tumors. What Sgouros and his colleagues have done is figure out how to reproducibly package much more powerful radioisotopes, called alpha-particle emitters that have the ability to kill cancer cells without damaging nearby normal cells, and they have tested how effectively they can treat mice with a very aggressive type of metastatic breast cancer. Early results show that they can pack a relatively large dose of radionuclides into the liposomes and substantially extend the life of treated mice. "This treatment is much less toxic than chemotherapy because it is targeted to tumor cells rather than to all rapidly dividing cells " says Sgouros. "Nanoparticles designed to deliver these powerful isotopes have a great potential in cancer therapy, particularly for metastatic disease." ABOUT MEDICAL PHYSICISTS If you ever had a mammogram, ultrasound, X-ray, MRI, PET scan, or known someone treated for cancer, chances are reasonable that a medical physicist was working behind the scenes to make sure the imaging procedure was as effective as possible. Medical physicists help to develop new imaging techniques, improve existing ones, and assure the safety of radiation used in medical procedures in radiology, radiation oncology and nuclear medicine. They collaborate with radiation oncologists to design cancer treatment plans. They provide routine quality assurance and quality control on radiation equipment and procedures to ensure that cancer patients receive the prescribed dose of radiation to the correct location. They also contribute to the development of physics intensive therapeutic techniques, such as the stereotactic radiosurgery and prostate seed implants for cancer to name a few. The annual AAPM meeting is a great re, providing guidance to physicists to implement the latest and greatest technology in a community hospital close to you. ABOUT AAPM The American Association of Physicists in Medicine (AAPM) is a scientific, educational, and professional organization of more than 6,000 medical physicists. Headquarters are located at the American Center for Physics in College Park, MD. Publications include a scientific journal ("Medical Physics"), technical reports, and symposium proceedings. American Institute of Physics (AIP)


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):